Business Information
The company's principal activity is to develop and apply proprietary genomic technologies to discover and evolve novel genes and gene pathways from diverse environmental sources. The company develops novel enzymes and other biological active compounds, such as small molecule drugs and monoclonal antibodies. The company's product solutions are used in pharmaceutical, agricultural and chemical processing and in industrial applications. The company's trademarks include diversa (R), gene site saturation mutagenesis, gssm, gigamatrix, pyrolase, genereassembly, diverselibrary, diverselibraries, pathwaylibrary, pathwaylibraries, directevolution (R), singlecell, scilect and streptomyces diversa. The company has strategic alliances with The Dow Chemical Company, Syngenta Biotechnology Inc, Celera Genomics, Invitrogen Corporation, Glaxosmithkline, PLC and others.
|
|
Name |
Title
|
Email
|
| Edward Shonsey | CEO | N/A | | Jeffrey Black | Chief Accounting Officer | N/A | | Anthony Altig | Sr. VP - Finance, Sec. | N/A | | John Malloy | Exec. VP - Biofuels Business Unit | N/A | | John McCarthy | CFO, Exec. VP | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 49,198 | (39,271) | | 2005 | 54,303 | (89,718) | | 2004 | 57,550 | (33,425)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
